EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-5.65%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.02B
AUM Growth
+$1.02B
(-5.8%)
Cap. Flow
+$84.8M
Cap. Flow
% of AUM
8.28%
Top 10 Holdings %
Top 10 Hldgs %
54.92%
Holding
96
New
13
Increased
32
Reduced
16
Closed
24
Top Buys
| 1 |
Sanofi
SNY
|
$44M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$26.4M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$22.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$19.1M |
| 5 |
AstraZeneca
AZN
|
$18.2M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$49M |
| 2 |
HCA Healthcare
HCA
|
$27.9M |
| 3 |
Masimo
MASI
|
$26.5M |
| 4 |
ARK Genomic Revolution ETF
ARKG
|
$21.6M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$16.2M |
Sector Composition
| 1 | Healthcare | 95.7% |
| 2 | Industrials | 1.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $92.2M | 6.56% | 632,794 -11,872 | -2% | -$1.73M |
|
2
United Therapeutics
UTHR
$13.8B
| $73.2M | 5.21% | 310,834 +18,600 | +6% | +$4.38M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $71M | 5.04% | 889,583 +279,644 | +46% | +$22.3M |
|
4
GSK
GSK
$79.9B
| $69.9M | 4.97% | 1,594,121 +334,959 | +27% | +$14.7M |
|
|
5
AstraZeneca
AZN
$248B
| $67.4M | 4.79% | 1,020,329 +275,066 | +37% | +$18.2M |
|
6
Danaher
DHR
$147B
| $45.6M | 3.24% | 179,659 +19,891 | +12% | +$5.05M |
|
|
7
Sanofi
SNY
$121B
| $44M | 3.13% | +879,460 | New | +$44M |
|
8
Avantor
AVTR
$9.18B
| $34.8M | 2.48% | 1,120,175 +124,943 | +13% | +$3.89M |
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $33.9M | 2.41% | 4,510,702 +367,100 | +9% | +$2.76M |
|
10
Community Health Systems
CYH
$387M
| $30.2M | 2.15% | 8,060,859 +934,148 | +13% | +$3.5M |
|
|
11
SPDR S&P Biotech ETF
XBI
$5.07B
| $26.4M | 1.88% | +356,067 | New | +$26.4M |
|
12
Envista
NVST
$3.52B
| $25.4M | 1.81% | 659,094 +89,743 | +16% | +$3.46M |
|
13
Biogen
BIIB
$19.4B
| $20.7M | 1.47% | 101,414 +23,411 | +30% | +$4.77M |
|
14
Elevance Health
ELV
$71.8B
| $20.6M | 1.47% | 42,785 +10,334 | +32% | +$4.99M |
|
|
AMRN
15
Amarin Corp
AMRN
$311M
| $19.8M | 1.41% | 13,284,894 +4,304,749 | +48% | +$6.41M |
|
16
Centene
CNC
$14.3B
| $19.8M | 1.41% | 233,647 +114,477 | +96% | +$9.69M |
|
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $19.1M | 1.36% | +994,362 | New | +$19.1M |
|
18
argenx
ARGX
$43.6B
| $18.6M | 1.32% | 49,136 +25,994 | +112% | +$9.85M |
|
19
Fate Therapeutics
FATE
$120M
| $18M | 1.28% | 726,586 +270,527 | +59% | +$6.7M |
|
20
Amneal Pharmaceuticals
AMRX
$3B
| $17.5M | 1.24% | 5,494,280 +2,783 | +0.1% | +$8.85K |
|
|
ABMD
21
DELISTED
Abiomed Inc
ABMD
| $17.2M | 1.22% | +69,297 | New | +$17.2M |
|
22
Natera
NTRA
$23.1B
| $16.9M | 1.2% | +475,655 | New | +$16.9M |
|
23
Guardant Health
GH
$8.41B
| $16.4M | 1.17% | 406,375 +193,172 | +91% | +$7.79M |
|
24
Tandem Diabetes Care
TNDM
$845M
| $15.2M | 1.08% | +256,268 | New | +$15.2M |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $14.9M | 1.06% | 552,388 -84,065 | -13% | -$2.27M |
|